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metabolic disorders, including insulin resistance and type 2 diabetes is increasing at alarming rates
worldwide, primarily as a result of poor lifestyle habits. In parallel, as the world population ages,
the prevalence of AD, the most common form of dementia in the elderly, also increases. In addition
to their epidemiologic and clinical association, mounting recent evidence indicates shared mecha-
nisms of pathogenesis between metabolic disorders and AD. We discuss the concept that peripheral
and central nervous system inflammation link the pathogenesis of AD and metabolic diseases. We
also explore the contribution of brain inflammation to defective insulin signaling and neuronal
dysfunction. Last, we review recent evidence indicating that targeting neuroinflammation may
provide novel therapeutic avenues for AD.
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Inflammation is part of the body’s defense mechanisms
against multiple threats, including infections and injury.
Inflammation is complex and involves both soluble factors
and specialized cells that are mobilized to neutralize and
fight threats to restore normal body physiology [1]. Similar
inflammatory processes are thought to occur in the
brain and in peripheral tissues. In the brain, glial cells,
especially astrocytes and microglia, undergo activation
under pro-inflammatory conditions. In a process similar
to that described for peripheral immune cells, activated
microglia in the central nervous system (CNS) increase
production of inflammatory cytokines. Both in the brain
and in peripheral tissues, unchecked or chronic inflamma-
tion becomes deleterious, leading to progressive tissue
damage in degenerative diseases.
Inflammation plays critical roles in the pathogenesis of
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and extremely costly for health programs in developed and
developing countries. Since the Rotterdam study was
published, suggesting that diabetes almost doubles the risk
of AD [2], a number of clinical and epidemiologic studies
have strengthened the link between these diseases [3–6].
Several studies have established further the presence of
inflammatory markers in the AD brain, including elevated
levels of cytokines/chemokines and gliosis (notably micro-
gliosis) in damaged regions [7–10]. A recent meta-analysis
showed that blood concentrations of several inflammatory
mediators, including tumor necrosis factor-alpha (TNF-a),
interleukin (IL) 6, and IL-1b are increased in AD patients
[11].
Overproduction of pro-inflammatory cytokines, including
TNF-a, is a key feature of the pathophysiology of metabolic
disorders. TNF-a is overexpressed in adipose tissue of obese
individuals [12], and landmark studies by Hotamisligil and
colleagues [12,13] demonstrated that elevated TNF-a
levels cause peripheral insulin resistance. Interestingly,
brain inflammation has recently been proposed to underlie
defective neuronal insulin signaling in AD [14]. Several
pathological features, including impaired insulin signalingeserved.
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diabetes and patients with AD. Therefore, it is likely that
mechanisms analogous to those that account for peripheral
insulin resistance in type 2 diabetes underlie impaired
brain insulin signaling and neuronal dysfunction in AD.
In the following sections, we discuss molecular/cellular
mechanisms underlying defective brain insulin signaling
and neuronal dysfunction in AD, with emphasis on evidence
that AD and diabetes share common inflammatory signaling
pathways.2. Elevated TNF-a and activation of stress kinases
underlie defective neuronal insulin signaling in AD
The molecular events and pathways leading to disrupted
brain insulin signaling in AD have only recently begun to be
unraveled. Insulin and insulin-like growth factor receptors
belong to the tyrosine kinase receptor family and signal
via insulin receptor substrate (IRS) proteins. These are
closely related, high-molecular weight proteins named
IRS-1 through IRS-4, of which IRS-1 and IRS-2 are the
most important and best studied [15,16]. Physiologically,
activation of insulin receptors (IRs) in peripheral tissues
stimulates tyrosine phosphorylation of IRS to initiate
intracellular signaling pathways. In type 2 diabetes,
elevated TNF-a levels trigger serine phosphorylation of
IRS-1 by stress kinases [13,17,18], which interferes with
its ability to engage in IR signaling and blocks the
intracellular actions of insulin [19–22]. Underlining its
role in disrupted insulin signaling, blockade of TNF-a in
obese mouse models results in improved insulin sensitivity
and glucose homeostasis [23,24].
In the brain, TNF-a is secreted mainly by microglial cells
in response to trauma, infection, or abnormal accumulation
of protein aggregates [25]. TNF-a levels are elevated in
AD cerebrospinal fluid and AD brain microvessels [26,27],
as well as in the brain of transgenic mouse models of AD
[28,29]. Initial evidence that impaired neuronal insulin
signaling in AD is linked to pro-inflammatory signaling
came from the finding that soluble oligomers of the
amyloid-b (Ab) peptide—synaptotoxins that accumulate
in AD [30,31]—cause IRS-1 inhibition through TNF-a
activation [14]. In fact, IRS-1 phosphoserine triggered
by Ab oligomers in hippocampal neurons is blocked by
infliximab, a TNF-a neutralizing antibody [14].
Ab oligomers have been shown to instigate removal of
IRs from the membranes of neuronal processes [32,33]
and to cause defective insulin signaling (revealed by
increased serine phosphorylation and reduced tyrosine
phosphorylation of IRS-1) in postmortem AD brains and
in several experimental models of AD [14,34,35]. Insulin
signaling in the CNS promotes neuronal survival
and regulates key processes underlying learning and
memory, including synapse density, dendritic plasticity,
and circuit function [36–38]. Thus, the induction of pro-
inflammatory pathways and ensuing defective insulinsignaling instigated by Ab oligomers are thought to be
linked to neuronal dysfunction in AD.
c-Jun N-terminal kinase (JNK) is the major intracellular
stress kinase linking TNF-a to inhibitory serine phosphory-
lation of IRS-1 in type 2 diabetes [13,20], and activated JNK
(pJNK) is also a feature of human obesity [39–41]. Ab
oligomer-induced activation of JNK was recently proposed
to participate in AD pathology. AD brains exhibit elevated
levels of pJNK [14,35], and increased pJNK has been
demonstrated in hippocampi of a transgenic mouse model
of AD and in cynomolgus monkeys that received
intracerebral infusions of Ab oligomers [14].
IkBa kinase (IKK), another stress kinase activated by
TNF-a in peripheral insulin resistance [42], also mediates
Ab oligomer-induced neuronal IRS-1 inhibition [14]. It
has now been established that overnutrition induces an
inflammatory response in peripheral metabolic tissues.
This form of metabolic inflammation, or “metaflammation,”
as proposed by Calay and Hotamisligil [43], causes
metabolic defects that underlie type 2 diabetes and obesity
[44,45]. In this context, IKK has been identified as a target
for anti-inflammatory therapy in obesity-associated type 2
diabetes [46]. Positive results were obtained in obese mice
treated with pharmacological inhibitors of IKK [47,48],
providing preclinical support to clinical trials aiming to
assess the potential benefit of salsalate, an inhibitor of
IKK, to type 2 diabetes patients [49]. The recently estab-
lished involvement of IKK in IRS-1 inhibition in AD pro-
vides additional evidence for a close parallelism between
inflammation-associated defective brain insulin signaling
in AD and chronic inflammation-induced insulin resistance
in peripheral tissues. Additional studies aiming to explore
the role of IKK in neuronal dysfunction are warranted and
may bring novel clues on mechanisms underlying AD pa-
thology.
The double-stranded RNA-dependent protein kinase
(PKR), originally identified as a pathogen sensor and a regu-
lator of the innate immune response against viral infections
in higher eukaryotes [50], can regulate or act in conjunction
with major inflammatory kinases/signaling pathways
implicated in metabolic homeostasis, including JNK
and IKK [51–53]. Interestingly, PKR is involved in Ab
oligomer-induced neuronal IRS-1 inhibition [14], rein-
forcing the hypothesis that common mechanisms underlie
peripheral insulin resistance in type 2 diabetes and impaired
brain insulin signaling in AD.
Current evidence thus indicates that pro-inflammatory
TNF-a signaling and activation of stress-sensitive kinases
play a key role in inducing IRS-1 inhibition and neuronal
dysfunction in AD (Fig. 1).3. Possible links between peripheral and CNS
inflammation
Inflammation in AD has been associated primarily with
activation of CNS-resident microglia induced by Ab
Fig. 1. Peripheral inflammatory mediators contribute to brain inflammation, neuronal insulin resistance, and neuronal dysfunction in Alzheimer’s disease.
Inflamm-aging [54], metaflammation [43] (as seen in obesity-related metabolic disorders, including type 2 diabetes and insulin resistance), and peripheral
infection/inflammation (caused by pathogens or systemic inflammatory disorders) give rise to states of chronic, low-grade systemic inflammation, leading
to overproduction of pro-inflammatory cytokines, such as tumor necrosis factor-a (TNF-a), interleukin (IL) 1b, and IL-6. Elevated levels of adipokines
may also link peripheral and central nervous system (CNS) inflammation in obesity. Peripheral inflammatory mediators cross the blood–brain barrier and,
in conjunction withmediators produced by activatedmicroglia, may lead to CNS inflammation. Activation of neuronal cytokine receptors (e.g., TNF-a receptor)
induces aberrant activation of stress kinases (c-Jun N-terminal kinase [JNK], IkBa kinase [IKK], and double-stranded RNA-dependent protein kinase [PKR]),
which phosphorylate insulin receptor substrate 1 (IRS-1) at serine residues and inhibit insulin-induced physiological tyrosine phosphorylation of IRS-1.
This interferes with the ability of IRS-1 to engage in insulin signaling and blocks the intracellular actions of insulin.
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cytokines can lead to several pathological features of AD.
Cytokines have been associated with increased tau
phosphorylation and decreased synaptophysin levels,
establishing their roles in cytoskeletal and synaptic
alteration in AD [56,57]. Targeting the increased
circulating levels of IL-1b with a neutralizing antibody has
been shown to reduce the activity of several tau kinases
and levels of phosphorylated tau (p-tau), and also to
reduce the load of oligomeric and fibrillar Ab in brains of
triple-transgenic AD mice (3xTg) [58]. Interestingly, treat-
ment with a drug targeting the p38 mitogen-activated protein
kinase pathway [59] was shown recently to normalize levels
of pro-inflammatory cytokines and to attenuate synaptic pro-
tein loss and impaired synaptic plasticity in AD mouse
models [60].
In addition, the clinical association between type 2
diabetes and AD has led to the hypothesis that periphery-
derived pro-inflammatory molecules could also influence
pathogenesis in the Central Nervous System (CNS)
(Fig. 1). Adipose tissue inflammation is one of the major
traits of diabetes and obesity [61,62], and both adipocytes
and adipose-resident macrophages may participate in acrosstalk between periphery and CNS. In obese patients, ad-
ipocytes react by producing pro-inflammatory cytokines,
adipokines, and chemokines, whereas resident macrophages
undergo a phenotypic change to a so-called M1, classically-
activated pro-inflammatory state [63]. This leads to
increased TNF-a, IL-1b, and IL-6 production, all of which
can cross the blood–brain barrier (BBB) [64]. Therefore,
adipose-derived inflammatory mediators could be an impor-
tant addition to cytokines produced by CNS-resident micro-
glia in triggering brain inflammation.
Fat-derived hormones, such as adiponectin and leptin,
have been associated with AD and could play a role in
connecting peripheral and central pathogenic mechanisms.
Adiponectin, derived from visceral fat, helps sensitize the
body to insulin by acting on receptors that are distributed
ubiquitously, including the brain [65–68]. Plasma
adiponectin levels are decreased in animal models of
obesity and in obese patients [69–71]. Plasma and
cerebrospinal fluid levels of adiponectin show a positive
correlation [72] and, intriguingly, recent studies found
increased levels of this adipokine in patients with mild
cognitive impairment and with AD [72,73]. It will be
interesting to determine the precise role, if any, of
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neuronal dysfunction in AD.
Leptin was found to reduce Ab generation and tau
phosphorylation in vitro [74,75], and leptin replacement
therapy induces hippocampal neurogenesis [76] and im-
proves cognitive performance [74] in transgenic models of
AD. Initially described for its role in satiety and long-term
body weight maintenance, leptin has recently been proposed
to regulate cognition, axonal growth, and synaptogenesis in
extrahypothalamic regions [77]. Lower plasma levels of
leptin have been associated with a fourfold increased risk of
development of AD in a 12-year follow-up period compared
with patients in whom leptin levels were greater [78].
Dyslipidemia is another important trait of metabolic
disorders. Cholesterol- and sphingolipid-enriched cell
membrane domains, called lipid rafts, appear to be preferen-
tial sites for Ab generation. In these microdomains, amyloid
precursor protein is cleaved preferentially through the
amyloidogenic pathway [79–81]. Particular types of
sphingolipids, namely ceramide and its metabolites, cause
inflammation [82,83], and have been increasingly
associated with type 2 diabetes [84]. Peripherally generated
ceramides can cross the BBB [85] and thus could contribute
to AD pathogenesis in two ways: (i) by changing the
microenvironment of lipid rafts, thereby favoring Ab
generation, and/or (ii) by inducing central inflammation
and disruption in neuronal insulin signaling [84].
Preclinical and clinical observations are accumulating
that support the notion that peripheral inflammatory
mediators link peripheral and central events in metabolic
dyshomeostasis and AD. Novel findings in this area could
potentially bring about advances for patients with type 2
diabetes and patients with AD, allowing for improved
prevention strategies for the former and raising hopes of
novel therapeutic approaches for the latter. As pointed out
recently, available evidence indicates that a healthy lifestyle
and long-term metabolic control are to be encouraged,
especially so for diabetic and obese patients, as a preventive
measure to reduce the risk of AD [86,87].4. Aging and other general causes of inflammation
Aging is the single most important risk factor for AD. The
concept of “inflamm-aging” was introduced by Claudio
Franceschi to define changes in the immune system that
accompany physiological aging, leading to chronic systemic
inflammation [54,88]. Inflammatory dyshomeostasis in
aging can result from loss of control over finely tuned
levels of pro- and anti-inflammatory cytokines, or as a
consequence of the incapacity to restore equilibrium after
it is perturbed by external factors. Whatever the underlying
causes, they can lead to a chronic state of low-grade
inflammation [89]. Interestingly, it has been proposed that
inflamm-aging is a result of lifetime exposure to acute and
chronic infections [90], with human longevity associated
at least in part with an increased capacity to maintain ainflammatory response at low levels [91]. Nevertheless, a
pro-inflammatory profile has also been described in
centenarians [90]. Increased levels of pro-inflammatory
cytokines and markers, such as IL-1b, IL-6, TNF-a, and
C-reactive protein [89], have been reported in “normal”
aging, but it is not clear whether this is a cause or a
consequence of aging. Inflammation, or rather the defective
ability to maintain low inflammation levels as one ages, may
contribute to the onset of AD (Fig. 1).
Additional conditions in which low-grade inflammation
can be maintained throughout a period of life include
recurrent or persistent infections (Fig. 1), and it is tempting
to speculate that chronically elevated peripheral inflamma-
tory mediators could be associated with accelerated
neuronal dysfunction and cognitive decline, or predispose
to earlier onset of AD [86]. Significantly, type 2 diabetes
induces changes in BBB permeability [92], and postmortem
analysis of diabetic AD brains showed increased levels of
IL-6 compared with nondiabetic AD brains [93]. Moreover,
the BBB of a transgenic mouse model of AD has been
reported to be more permeable to peripheral inflammatory
cytokines [94]. These findings raise the possibility that AD
brains could be more susceptible to changes in peripheral
inflammatory dyshomeostasis.5. Anti-inflammatory therapies for AD?
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a
heterogeneous family of cyclooxygenase (COX) inhibitors.
Their therapeutic outcomes vary according to their
specificity toward the two known isoforms of the enzyme,
COX-1 and COX-2 [95]. Early reports on patients treated
chronically with anti-inflammatory drugs for rheumatoid
arthritis or leprosy [96,97] found that a 2-year treatment
with NSAIDs reduced significantly the risk of AD later in
life [98], and that clinical benefit increased with longer
periods of treatment [99]. Similar results were reported for
patients using aspirin [99] or combined NSAID/steroid
therapy [100]. On the other hand, subsequent studies failed
to find a correlation between NSAID use and AD risk
[101,102]. Intriguingly, considerable variability was found
even among studies that showed beneficial actions of
NSAIDs, possibly reflecting differences in dosage, period
of treatment, and patient age. Benefits were observed
when anti-inflammatory drugs were used well before
the onset of dementia [103] and might be limited to apolipo-
protein E4-carrying patients [104].
Results from the observational studies described here
encouraged the search for molecular mechanisms that could
explain the positive effects of NSAIDs in delaying/prevent-
ing AD. Interestingly, certain NSAIDs, such as ibuprofen,
indomethacin, and sulindac sulfide, were shown to decrease
Ab42 production by up to 80% in cultured cells, apparently
via a COX-independent mechanism [105]. Mice overex-
pressing amyloid precursor protein and treated with
ibuprofen also showed a significant reduction in cortical
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tion [106]. Neurons treated with COX-1 preferential inhibi-
tors, such as ibuprofen and aspirin, were more resistant to Ab
toxicity than neurons treated with COX-2-specific inhibitors
[107]. In line with this finding, Kotilinek and colleagues
[108] reported improved synaptic plasticity and memory
formation in AD transgenic mice treated with COX-2- but
not COX-1-selective inhibitors.
Despite the initial optimism generated by these observa-
tions, randomized clinical trials provided disappointing
results that did not support disease-modifying or beneficial
actions of NSAIDs in AD [109–114]. As suggested
previously [103], such trials might have failed in finding
positive effects of NSAIDs for one or more of the following
reasons: (i) most trials tested NSAIDs for treatment of
clinically established AD, whereas epidemiologic data
supported a positive effect of anti-inflammatory agents
before clinical onset of symptoms; and (ii) beneficial effects
may be specific to anti-inflammatory drugs capable of
reducing Ab levels (the so-called selective Ab-lowering
agents). Thus, general testing of several members of the
large NSAID family may have generated conflicting results.
Renewed hopes for an effective AD treatment based on
anti-inflammatory therapy came from a report that perispinal
administration of etanercept, an anti-TNF-a fusion protein,
improved cognitive performance of patients with AD in a
6-month pilot study [115], followed by another report on
rapid cognitive improvement (within minutes) on etanercept
administration to one patient with late-onset AD [116].
Despite their possible significance, additional clinical
studies using larger cohorts and patients at different stages
of the disease are needed to validate these initial findings.
In this regard, two clinical trials are currently under way
[49] to investigate the possible benefit of etanercept to treat
mild/moderate AD.
Anti-TNF-a strategies for AD have received further
support from experimental findings using the neutralizing
antibody infliximab. Intracerebroventricular infusion of
infliximab in AD transgenic mice reduced the number of
amyloid plaques and the levels of p-tau [117]. The samegroup
subsequently reported cognitive improvement in one patient
with AD after intrathecal administration of infliximab
[118]. Clinical trials are currently investigating the efficacy
of infliximab in a wide range of pathologies, including major
depression, obesity-associated insulin resistance, and
diabetic complications, among many others [49]. There are
no trials, however, investigating specifically the safety and
efficacy of infliximab to treat patients with AD. Given the
evidence indicating a role of TNF-a in the pathogenesis of
AD [119], clinical trials using infliximab appear warranted.
Neither etanercept nor infliximab cross the BBB,
thus requiring invasive forms of central administration.
Thalidomide, on the other hand, is a BBB-permeable drug
that has attracted increasing attention because of its
anti-inflammatory actions related to the inhibition of TNF-a
production [120]. When given intraperitoneally, boththalidomide and a synthetic analog (3,60-dithiothalidomide
[3,60-DTT] [121]) inhibited lipopolysaccharide-induced
increases in TNF-a messenger RNA and protein levels
in the cortex [122] and hippocampus [123] of rodents.
3,60-DTT, but not thalidomide, reversed cognitive impairment
in 3xTg mice in the eight-arm radial maze [122] and in the
Morris Water Maze [123]. Whether 3,60-DTT also rescues
brain levels of synaptic proteins, p-tau, and Ab42 remains
controversial [122,123]. Thalidomide also protected rats
from neuronal loss induced by intrahippocampal Ab42
injection [124]. Thalidomide is now in a phase 2 clinical trial
to treat mild to moderate AD, and results will establish its
potential value in preventing or halting the progression ofAD.6. Conclusion
CNS inflammation, impaired neuronal insulin signaling,
and neuronal dysfunction in AD may be a consequence of
systemic inflammatory processes that occur throughout life
[86,87]. Inflammatory mediators—notably pro-inflammatory
cytokines such as TNF-a, IL-6, and IL-1b—may play a role
in the crosstalk between peripheral tissues and the brain.
Inflamm-aging [54], metaflammation [43], and peripheral
infection/inflammation caused by pathogens or systemic
inflammatory disorders may give rise to chronic, low-grade
inflammation. Ultimately, this could contribute to or
accelerate the onset of clinical manifestations of AD.
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